Photometric Activity Assay

ZediExclusive Tissue Transglutaminase Assay Kit

(Chromogenic activity assay optimized for tissue transglutaminase, also suitable for epidermal transglutaminase)

1 Kit 415 € available

Art. No. Z010
Background info TG2 is present in various tissues and involved in a plentitude of physiological as well as pathological processes. The enzyme catalyses the acyl transfer reaction between the γ-carboxyamide group of peptidebound glutamine residues and a variety of primary amines, particularly the ε-amino group of lysine (Lorand L. et al., 1962). This assay enables the measurement of TG2 activity according to the chromogenic hydroxamate detection principle (Grossowicz, N. et al., 1950).
Assay principle The TISSUE TRANSGLUTAMINASE ASSAY KIT uses Z-QQPF as the amine acceptor substrate and hydroxylamine as amine donor. In the presence of tTG hydoxylamine is incorporated into Z-QQPF to form Z-glutamylhydroxamate-QPF which develops a colored complex with iron (III) detectable at 525 nm.

Activity measurement of TG2
Reagents in the kit (1A) ACTIVITY REAGENT 1A: lyophilized MOPS buffer pH 7.6 containing Z-QQPF, DTT and calcium, 3 vials
(2A) ACTIVITY REAGENT 2A: Hydroxylamine, 3 vials
(3S) STOP REAGENT 3S: Hydrochloric acid [4% v/v], Iron (III) chloride, 3 vials
(4P) TG2 POSITIVE CONTROL 4P: lyophilized TG2, 3 vials
Equipment The TISSUE TRANSGLUTAMINASE ASSAY KIT can be used in standard spectrophotometers with polystyrene 1 mL cuvettes or MTP. Refer to the instructions of the manufacturer.
Intended use Determination of tissue transglutaminase activity (tTG, TG2). Kit is sufficient for 3 x 11 measurements in cuvettes or 3 x 36 measurements in 96 well microtiter plates (MTP).
Storage 4P has to be stored at -20°C (shipment is possible at 4 – 8°C).
1A, 2A, 3S has to be stored at 4 – 8°C. The unopened reagents are at least stable until the expiration date printed on the box.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA